The DESTINY-Lung02 evaluated the benefit-risk profile of T-DXd at 5.4 and 6.4 mg/kg in patients with previously treated HER2-mutant metastatic NSCLC. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.